论文部分内容阅读
目的评价阿德福韦对比恩替卡韦治疗慢性乙型病毒性肝炎(乙肝)的临床疗效及安全性。方法 86例慢性乙肝患者随机分为阿德福韦组(41例)和恩替卡韦组(45例),分别口服阿德福韦0.5 mg·d-1和恩替卡韦10 mg·d-1,疗程均为12个月。比较2组患者治疗前后乙肝病毒(HBV)DNA载量、病毒转阴率及药品不良反应。结果治疗12个月后,阿德福韦组与恩替卡韦组患者HBV DNA病毒载量[(4.21±0.71)vs(4.01±0.68)log10copies·m L-1]较治疗前均明显降低,差异有统计学意义(P<0.05)。2组HBV DNA转阴率及谷丙转氨酶(ALT)正常率差异无统计学意义(P>0.05)。2组患者不良反应发生率差异无统计学意义(P>0.05)。结论阿德福韦与恩替卡韦治疗慢性乙肝均有较好的临床疗效,且不良反应轻微。
Objective To evaluate the clinical efficacy and safety of adefovir versus entecavir in the treatment of chronic hepatitis B (hepatitis B). Methods Eighty-six patients with chronic hepatitis B were randomly divided into adefovir group (n = 41) and entecavir group (n = 45). Adefovir 0.5 mg · d-1 and entecavir 10 mg · d- 12 months. Before and after treatment, HBV DNA load, virus negative rate and drug adverse reactions were compared between the two groups. Results After 12 months of treatment, the HBV DNA viral load in adefovir group and entecavir group was significantly lower than that before treatment [(4.21 ± 0.71) vs (4.01 ± 0.68) log10 copies · m L-1], with statistical difference Significance (P <0.05). There was no significant difference in the negative rate of HBV DNA and the normal rate of alanine aminotransferase (ALT) between the two groups (P> 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Both adefovir and entecavir have good clinical efficacy in the treatment of chronic hepatitis B with mild side effects.